Israeli biotech company Gamida Cell has secured approval from the US Food and Drug Administration (FDA) for Omisirge (omidubicel-onlv), an allogeneic cell therapy. We extend our warmest congratulations to Gamida Cell on reaching this long waited and crucial milestone, which sets new treatment horizons for the cancer patients.
We congratulate Prof. Peled, the Head of The Goldyne Savad Institute of Gene Therapy, who had a fundamental role in the development of cord blood stem cell and NK expansion technology of Gamid Cell Ltd and supported the program since its initiation in 2006 through phase I/II and into Phase III clinical studies to FDA approval.